Abstract | BACKGROUND: The review was conducted to evaluate from the literature the safety of hormonal methods of contraception in women with liver tumors, specifically in benign and malignant disease. STUDY DESIGN: We searched PubMed and Cochrane databases to find all articles published from database inception through July 2008 that were relevant to hormonal contraception use and liver tumors. RESULTS: CONCLUSIONS: The studies identified examined oral contraceptive use among women with FNH. We did not identify any studies of hormonal contraceptive use among women with hepatocellular adenoma or with malignant liver tumors. Limited, poor-quality evidence suggests that for women with FNH, use of low-dose COCs or POCs does not appear to influence either liver lesion resolution or progression.
|
Authors | Nathalie Kapp, Kathryn M Curtis |
Journal | Contraception
(Contraception)
Vol. 80
Issue 4
Pg. 387-90
(Oct 2009)
ISSN: 1879-0518 [Electronic] United States |
PMID | 19751862
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review, Systematic Review)
|
Chemical References |
- Contraceptives, Oral, Hormonal
|
Topics |
- Adenoma, Liver Cell
- Contraceptives, Oral, Hormonal
(adverse effects)
- Female
- Focal Nodular Hyperplasia
- Humans
- Liver Neoplasms
- Risk Factors
|